Skip to main content

Table 2 Types of nucleotide alterations

From: Mutational signatures among young-onset testicular cancers

Gene 20–29 30–39  > 40 p-value
(20–29 vs. > 40)
p-value
(30–39 vs. > 40)
p-value
(continuous age)
C > A 1510 (21%) 1268 (21%) 582 (18%) 0.085 0.10 0.18
C > G 896 (12%) 742 (12%) 460 (15%) 0.15 0.22 0.18
C > T 2712 (37%) 2220 (37%) 1120 (36%) 0.94 0.76 0.80
T > A 566 (8%) 440 (7%) 240 (8%) 0.79 0.86 0.79
T > C 1182 (16%) 986 (16%) 518 (16%) 0.64 0.82 0.90
T > G 494 (7%) 352 (6%) 228 (7%) 0.54 0.12 0.82
  1. Prevalence of somatic nucleotide alterations among testicular tumors diagnosed at ages 20–29 (n = 59), 30–39 (n = 54), and age 40 or older (n = 21). Entries are number (proportion) of mutations type in each age of onset group. Differences in types of nucleotide laterations by age at onset groups were tested using a logistic regression model * indicates statistical significance at a .05 level